Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[The therapy of acute myeloid leukemia in patients of advanced age].
Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: fonatsch c. Dtsch Med Wochenschr. 1999 Aug 27;124(34-35):1005-14. doi: 10.1055/s-2007-1024465. Dtsch Med Wochenschr. 1999. PMID: 10488328 Review. German. No abstract available.
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: fonatsch c. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C, Haferlach T, Haase D, Fonatsch C, Löffler H, Schlegelberger B, Staib P, Sauerland MC, Heinecke A, Büchner T, Hiddemann W; German AML Cooperative Study Group. Schoch C, et al. Among authors: fonatsch c. Br J Haematol. 2001 Jan;112(1):118-26. doi: 10.1046/j.1365-2141.2001.02511.x. Br J Haematol. 2001. PMID: 11167792 Free article. Clinical Trial.
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. Büchner T, et al. Among authors: fonatsch c. J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133. J Clin Oncol. 2003. PMID: 14673036 Clinical Trial.
Improved outcome in adult B-cell acute lymphoblastic leukemia.
Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Löffler H, Fonatsch C, Rieder H, Heil G, Heinze B, Arnold R, Hossfeld D, Büchner T, Koch P, Freund M, Hiddemann W, Maschmeyer G, Heyll A, Aul C, Faak T, Kuse R, Ittel TH, Gramatzki M, Diedrich H, Kolbe K, Fuhr HG, Fischer K, Schadeck-Gressel C, Weiss A, Strohscheer I, Metzner B, Fabry U, Gökbuget N, Völkers B, Messerer D, Uberla K. Hoelzer D, et al. Among authors: fonatsch c. Blood. 1996 Jan 15;87(2):495-508. Blood. 1996. PMID: 8555471 Free article.
Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
Schwartz S, Heinecke A, Zimmermann M, Creutzig U, Schoch C, Harbott J, Fonatsch C, Löffler H, Büchner T, Ludwig WD, Thiel E. Schwartz S, et al. Among authors: fonatsch c. Leuk Lymphoma. 1999 Jun;34(1-2):85-94. doi: 10.3109/10428199909083383. Leuk Lymphoma. 1999. PMID: 10350335
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A. Büchner T, et al. Among authors: fonatsch c. Blood. 1999 Jun 15;93(12):4116-24. Blood. 1999. PMID: 10361108 Free article. Clinical Trial.
Management of acute myeloid leukemia in elderly patients.
Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, Büchner T. Hiddemann W, et al. Among authors: fonatsch c. J Clin Oncol. 1999 Nov;17(11):3569-76. doi: 10.1200/JCO.1999.17.11.3569. J Clin Oncol. 1999. PMID: 10550156 Review.
255 results